Peripheral arterial occlusive disease (PAOD) may be associated with knee osteoarthritis (OA), according to data presented at the 7th Association of South-East Asian Pain Societies (ASEAPS) Congress 2017, held in Yangon, Myanmar.
Joint mobilization, ultrasound therapy and therapeutic exercises may improve the range of motion of the ankle and decrease pain in patients with tibia and fibula fractures after cast removal, reports a study presented at the 7th Association of South-East Asian Pain Societies (ASEAPS) Congress 2017.
Patients with early rheumatoid arthritis (RA) may benefit from the initial addition of certolizumab pegol (CZP) to optimized methotrexate (MTX) therapy, as this strategy potentially prevents joint destruction, according to the results of the phase III C-OPERA* study.
Fidaxomicin shows potential for treating Clostridium difficile infection (CDI), with response and recurrence being significantly better in patients with a first CDI episode than in those with prior episodes, according to data from an open-label study.
A minimum of 45 minutes of physical activity per week may be suitable for functional improvement in adults with lower extremity conditions, a recent study found.
Concomitant statin therapy was associated with an attenuation of tocilizumab (TCZ)-mediated increase in serum lipids in patients with rheumatoid arthritis (RA), according to a recent post hoc analysis of randomized clinical studies.
The oral Janus kinase 1 inhibitor filgotinib produces rapid improvements in the signs and symptoms of active rheumatoid arthritis when used either alone or in combination with methotrexate, two 24-week phase IIb trials suggest.
Patients with early arthritis should be allowed to share in the decision making regarding the approach to treatment, with rheumatologists acting as the primary specialists, according to the 2016 update of the European League Against Rheumatism (EULAR) recommendations for early arthritis management.
Bariatric surgery (gastric banding and gastric bypass) may reduce the risk and improve the prognosis of psoriasis and psoriatic arthritis in obese patients, a study from Denmark shows.
Secukinumab is safe and effective for ankylosing spondylitis (AS), producing improvements in AS signs/symptoms that can be maintained through 2 years of continuous therapy and with no new safety issues, according to data from the phase III MEASURE 1 study.